In in vitro studies, 0.1 μM and 1 μM DS‐1205c in combination with osimertinib (2 μM), slowed the growth of NCI‐H1975 cells, which is a human NSCLC cell line harboring T790M and L858R EGFR mutations,11 with relative growth rates of 43.1% and 2.2%, respectively. Here, EGFR is linked to non-small cell lung carcinoma.